این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
گوارش، جلد ۲۸، شماره ۴، صفحات ۲۴۷-۲۵۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Ivermectin-Induced Liver Injury Due to Self-Medication in SARS-CoV-2 Infection
چکیده انگلیسی مقاله Background : With the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posing a global health emergency, self-medication with ivermectin has been observed in certain Latin American countries. This study aimed to characterize the clinical features of liver injury associated with ivermectin when used as self-medication for treating  coronavirus disease 2019 (COVID-19). Materials and Methods:   We reviewed the clinical records of patients diagnosed with severe COVID-19 at the Emergency Room of Rebagliati Hospital in Lima, Peru, in March 2021. The criteria of the Drug-Induced Liver Injury (DILI) Expert Working Group and the Council for International Organizations of Medical Sciences/Roussel Uclaf Causality Assessment Method (CIOMS/RUCAM) were utilized to establish the diagnosis of drug-induced liver injury and assess causality, respectively. Results: We report five cases of ivermectin-induced liver injury (IILI), comprising four men and one woman, with a mean age of 49.3±12.3 years. The mean daily dose, duration, and total dose of ivermectin were 32.9±21.8 mg/day, 2.6 ± 0.6 days, and 89.6±71.4 mg, respectively. On average, IILI occurred 11±3.8 days after the initiation of treatment, and none of the cases developed jaundice. The mean levels of alanine aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase were elevated 8±4.4, 1.7±0.9, and 10.9±5.0 times above the upper limit of normal, respectively. Two patients exhibited a hepatocellular pattern, two had a mixed pattern, and one displayed a cholestatic pattern. All cases were classified as mild and achieved recovery. Causality assessment categorized four cases as "possible" and one case as "highly probable." Conclusions: The findings emphasize the need for further pharmacovigilance studies on IILI when used for COVID-19 treatment.
کلیدواژه‌های انگلیسی مقاله Ivermectin,COVID-19,Drug-induced liver injury,Adverse drug reaction,SARS-CoV-2,Liver injury
نویسندگان مقاله | Teodoro J Oscanoa
-Universidad Nacional Mayor de San Marcos, Facultad de Medicina. Lima Perú -Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima Perú


| José Amado-Tineo
Departamento de Emergencia del hospital Rebagliati EsSalud, Lima, Perú


| Javier Matta-Pérez
Departamento de Emergencia del hospital Rebagliati EsSalud, Lima, Perú


| Waldo Taype-Huamaní
Centro de Estudios sobre la Seguridad de los Medicamentos (CESME), Universidad de Valladolid, Valladolid, Spain


| Alfonso Carvajal
Discipline of Medical Gerontology, Trinity College Dublin, Mercer's Institute for Successful Ageing, St James's Hospital, Dublin, Ireland


| Roman Romero-Ortuno


نشانی اینترنتی http://govaresh.org/index.php/dd/article/view/2597
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات